Inclisiran + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Familial Hypercholesterolemia - Heterozygous
Conditions
Familial Hypercholesterolemia - Heterozygous
Trial Timeline
Dec 9, 2024 → Apr 15, 2029
NCT ID
NCT06597019About Inclisiran + Placebo
Inclisiran + Placebo is a phase 3 stage product being developed by Novartis for Familial Hypercholesterolemia - Heterozygous. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06597019. Target conditions include Familial Hypercholesterolemia - Heterozygous.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06597006 | Phase 3 | Recruiting |
| NCT06597019 | Phase 3 | Recruiting |
| NCT04659863 | Phase 3 | Completed |
| NCT04652726 | Phase 3 | Completed |
| NCT03705234 | Phase 3 | Active |
Competing Products
20 competing products in Familial Hypercholesterolemia - Heterozygous
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Rosuvastatin 20mg + Placebo | AstraZeneca | Phase 3 | 77 |
| rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin 20mg | AstraZeneca | Phase 3 | 77 |
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Statins and Ezetimibe | Merck | Pre-clinical | 23 |
| Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo | Merck | Phase 3 | 77 |
| MK-0524A + MK-0524A | Merck | Phase 1 | 33 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| DFV890 | Novartis | Phase 2 | 52 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Inclisiran Sodium for injection + Placebo + Placebos | Novartis | Phase 3 | 77 |
| LCQ908 + Placebo | Novartis | Phase 3 | 77 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |